EIB provides Minoryx with up to €25M to support development of breakthrough therapies in orphan neurodegenerative diseases

30/10/2020 Press release EUROPEAN INVESTMENT BANK PROVIDES MINORYX WITH UP TO €25M TO SUPPORT DEVELOPMENT OF BREAKTROUGH THERAPIES IN ORPHAN NEURODEGENERATIVE DISEASES. EIB support to develop breakthrough treatmentsto address orphan neurodegenerative diseases with high unmet medical needs Focus on Minoryx’s lead asset, leriglitazone, a novel, disease-modifying PPAR-γ agonist Venture debt operation supported by the Investment…